Stay updated on Brexucabtagene Autoleucel in B-precursor ALL Clinical Trial
Sign up to get notified when there's something new on the Brexucabtagene Autoleucel in B-precursor ALL Clinical Trial page.

Latest updates to the Brexucabtagene Autoleucel in B-precursor ALL Clinical Trial page
- Check2 days agoChange DetectedA five-year follow-up publication for ZUMA-3 was added, reporting on brexucabtagene autoleucel treatment in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.SummaryDifference0.0%

- Check9 days agoChange DetectedThe ZUMA-3 record is displayed with detailed information about the brexucabtagene autoleucel study, including its protocol, eligibility criteria, outcome measures, participating locations, and publications. The record also indicates that the study is completed and is no longer recruiting participants.SummaryDifference88%

- Check16 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the page otherwise continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner announces NIH website updates and a transition to using “Super Intelligence” in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check30 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to Brexucabtagene Autoleucel in B-precursor ALL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brexucabtagene Autoleucel in B-precursor ALL Clinical Trial page.